GLP-1 Medications and Menopause: What the Research Shows

The menopausal transition is the single most predictable inflection point for weight gain in a woman's life. Across the SWAN cohort and large European registries, women gain an average of 1.5 lb (0.7 kg) per year through perimenopause and continue accumulating weight for several years after the final menstrual period — but the more important change is where the weight goes. Visceral adipose tissue, the metabolically active fat that wraps the abdominal organs and drives cardiometabolic risk, roughly doubles as a fraction of total body fat after menopause. That biology is what makes the menopause transition such a hard target for diet and exercise alone, and it is the reason GLP-1 receptor agonists have become one of the most consequential clinical tools for women in midlife.

The question women and their clinicians actually want answered is narrower than "do GLP-1s work for weight loss?" It is: do they work as well in perimenopausal and postmenopausal women, where lower estrogen, sarcopenia, and shifting fat distribution all stack against weight loss? And does menopausal hormone therapy change the answer? Three large datasets published between 2024 and 2026 — a SURMOUNT post hoc analysis, a retrospective semaglutide cohort, and a Mayo Clinic tirzepatide cohort with hormone therapy — now make it possible to answer that more precisely than ever before.

Why Menopause Changes the Weight-Loss Equation

The biology of midlife weight gain is not a slowdown in willpower. It is a measurable rewiring of energy balance. Lovejoy and colleagues followed 156 premenopausal women longitudinally through the menopausal transition and quantified the change directly: resting energy expenditure fell, visceral fat accumulated independently of total weight gain, and the shift was driven by the menopausal transition itself rather than chronological aging.

Evidence: "The transition to menopause is associated with increased visceral adipose tissue and decreased energy expenditure, independent of aging." — Lovejoy JC, et al. International Journal of Obesity. 2008. DOI: 10.1038/ijo.2008.25

The estrogen decline of perimenopause and the menopausal transition does three things simultaneously that work against weight loss:

Fat redistribution. Subcutaneous fat shrinks and visceral fat expands. The android pattern raises insulin resistance and drives the cardiometabolic risk profile that obesity medicine guidelines now treat as a separate target from BMI.
Lower resting energy expenditure. Even when controlled for fat-free mass changes, the menopausal transition lowers resting metabolic rate. Fewer calories are burned at rest, and the same caloric intake produces a slow positive balance.
Loss of skeletal muscle. Sarcopenia accelerates from age 50, removing the largest contributor to whole-body glucose disposal and basal metabolism.

The combined effect is roughly 200–300 kcal/day of negative drift in maintenance energy balance — small per day, structural over a decade. That is the headwind any pharmacotherapy is fighting against.

Tirzepatide Works as Well in Menopause as Before It

The largest dataset addressing this question is a 2025 post hoc analysis of the SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 trials. Tchang and colleagues categorized 2,542 women in the trials by reproductive stage — premenopausal, perimenopausal, or postmenopausal — and re-analyzed weight loss by group. The conclusion was unambiguous: tirzepatide produced clinically and statistically meaningful weight loss across all three groups, and the difference between premenopausal and post-/perimenopausal women on the maximum tolerated dose was small.

Evidence: "In SURMOUNT-1, significantly greater body weight reductions from baseline were observed with tirzepatide versus placebo in women in the premenopause (−26% vs. −2%), perimenopause (−23% vs. −3%), and postmenopause (−23% vs. −3%) stages." — Tchang BG, et al. Obesity. 2025. DOI: 10.1002/oby.24254

The 3-percentage-point gap between premenopausal and postmenopausal women is real but modest, and it is dwarfed by the 20-plus point gap between active drug and placebo in every reproductive stage. Importantly, the analysis also showed that waist circumference and waist-to-height ratio — the surrogates that track visceral adiposity — improved similarly across all reproductive stages. That matters because visceral fat is what menopause preferentially adds.

The practical interpretation is straightforward: menopause does not blunt tirzepatide's efficacy. Postmenopausal women starting at the same BMI as a 35-year-old can expect a similar magnitude of weight loss, with the same safety and tolerability profile observed in SURMOUNT-1 (starting GLP-1 expectations are reviewed here).

Semaglutide and the Hormone Therapy Question

The story for semaglutide is similar in magnitude but adds an important wrinkle. Salamun and colleagues studied 76 postmenopausal women treated with semaglutide for weight loss, comparing those who were also on systemic menopausal hormone therapy with those who were not.

Evidence: "Semaglutide treatment was associated with significant weight loss in postmenopausal women, and this was greater in women using menopause hormone therapy compared with those not using hormone therapy at 3, 6, 9, and 12 months." — Salamun V, et al. Menopause. 2024. PubMed: 38446869

That observation — that estrogen exposure correlates with deeper response to a GLP-1 — is biologically plausible. Preclinical work has shown that estrogen modulates GLP-1 signaling in the hypothalamic appetite circuits, and rodent models show synergy between estrogen receptor activation and GLP-1 receptor agonism on food intake and body weight. A retrospective cohort cannot prove causation, but the size and direction of the effect have now been replicated.

The same baseline trial response remains intact. Wilding and colleagues' STEP 1 trial established the reference number for semaglutide 2.4 mg, and women across menopausal status in that trial achieved approximately the headline figure.

Evidence: "Mean change in body weight from baseline to week 68 was −14.9% in the semaglutide group as compared with −2.4% with placebo." — Wilding JPH, et al. New England Journal of Medicine. 2021. DOI: 10.1056/NEJMoa2032183

Postmenopausal subgroup analyses of STEP 1 and pooled OASIS data show body weight reductions in the 14–16% range — within rounding distance of the all-comers number, and substantially better than what diet and exercise produce in this population.

The Tirzepatide-Plus-Hormone-Therapy Signal

The most provocative recent finding is from a Mayo Clinic retrospective cohort published in early 2026. Castaneda and colleagues compared 40 postmenopausal women receiving tirzepatide plus menopausal hormone therapy with 80 matched women receiving tirzepatide alone, over a median of 18 months of treatment.

Evidence: "After 18 months, women using both tirzepatide and menopause hormone therapy lost 17% of total body weight compared with 14% in women using tirzepatide alone — a 35% relative increase in weight loss with concurrent hormone therapy." — Castaneda R, et al. Lancet Obstetrics, Gynaecology, & Women's Health. 2026. DOI: 10.1016/S3050-5038(25)00145-1

The cardiometabolic surrogates moved in the same direction. Triglycerides, fasting glucose, and the visceral-fat surrogate of waist circumference all improved more in the combined group. The authors are explicit that this was not a randomized trial — the women who chose hormone therapy may differ systematically from those who did not — but the size of the absolute difference (≈3 percentage points) and the consistency with the semaglutide cohort make a real biological effect the most parsimonious explanation.

What This Does and Does Not Mean

The current evidence supports three reasonable conclusions and rules out a fourth:

Conclusion	Strength of evidence
Tirzepatide and semaglutide produce 14–23% weight loss in peri- and postmenopausal women	High — multiple trial subgroups
Concurrent menopausal hormone therapy is associated with deeper weight loss on GLP-1s	Moderate — two cohorts, biologically plausible mechanism
Visceral fat and waist circumference respond similarly across reproductive stages	High — SURMOUNT post hoc
Hormone therapy should be started for the purpose of amplifying GLP-1 weight loss	Not supported — RCT evidence does not yet exist

The last row is the crucial caveat. Hormone therapy is prescribed for the management of vasomotor symptoms and the prevention of bone loss in appropriate candidates. Whether the GLP-1-amplifying effect alone justifies starting hormone therapy in a woman with no menopausal symptoms is not something current data can answer.

How Clinicians Are Using This in Practice

Two practical patterns have emerged in midlife obesity medicine:

Don't undertreat postmenopausal women. The pre-2024 narrative — that older women would lose less weight on GLP-1s and so should be triaged to lower-priority care — is not supported by the SURMOUNT post hoc data. Maximum tolerated doses produce similar percentage losses regardless of menopausal stage.
Co-management matters. A woman on tirzepatide for obesity and on transdermal estradiol/oral progesterone for vasomotor symptoms is increasingly the norm, not the exception. Coordination between the obesity-medicine clinician and the gynecologist is now the practical bottleneck, not pharmacology.

Resistance training is a particularly important adjunct in this group because of the muscle-loss risk on GLP-1 therapy, which compounds with menopause-associated sarcopenia. Protein intake at 1.2–1.6 g/kg of goal body weight, two to three resistance-training sessions per week, and DXA monitoring at 6–12 months are reasonable defaults for postmenopausal women on a GLP-1.

Key Takeaways

Menopause shifts the energy-balance equation against weight loss through visceral fat accumulation, lower resting energy expenditure, and accelerated sarcopenia — not because of willpower or motivation.
Tirzepatide produces 23% weight loss in peri- and postmenopausal women in SURMOUNT-1, only 3 percentage points behind premenopausal women on the same dose, and with similar visceral-fat improvement.
Semaglutide subgroup data show 14–16% weight loss in postmenopausal women, in line with the all-comers STEP 1 number.
Concurrent menopausal hormone therapy is associated with ~3 percentage points of additional weight loss on tirzepatide and a stronger response on semaglutide — biologically plausible but not yet confirmed by a randomized trial.
Hormone therapy is not a weight-loss drug. Its appropriate use case remains symptom management and bone protection, with the GLP-1 synergy being a beneficial adjacency rather than an indication.
Muscle preservation matters more here than in younger patients. The sarcopenia of menopause and the muscle-loss signal of GLP-1 therapy compound, and resistance training plus adequate protein should be standard.

The clinical translation of all of this is simple: a 55-year-old woman with obesity and vasomotor symptoms is one of the best candidates for GLP-1 therapy in modern obesity medicine, not one of the worst. The biology of menopause is what made midlife weight loss so difficult before semaglutide and tirzepatide existed — and it is largely what these drugs are now solving.

References

Tchang BG, Aras M, Kumar RB, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity. 2025;33(5):851–860. DOI: 10.1002/oby.24254
Castaneda R, Acosta A, Ghusn W, et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. The Lancet Obstetrics, Gynaecology, & Women's Health. 2026. DOI: 10.1016/S3050-5038(25)00145-1
Salamun V, Verdenik I, Imamovic Kumalic S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31(4):266–274. PubMed: 38446869
Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. International Journal of Obesity. 2008;32(6):949–958. DOI: 10.1038/ijo.2008.25
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989–1002. DOI: 10.1056/NEJMoa2032183
Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. DOI: 10.1172/jci.insight.124865
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205–216. DOI: 10.1056/NEJMoa2206038

Last updated: 2026-04-30 Medical review: Dr. James Chen, MD, PhD, FACE